MacroGenics reports FY2024 net loss of $67M; discontinues vobra duo development

MACROGENICS INC

Net loss of $67.0M ($1.07 diluted EPS) for FY2024 vs. net loss of $9.1M ($0.15) in FY2023.
Total revenue $150.0M, up from $58.7M in FY2023, driven by $85M milestone from Incyte.
Cash, cash equivalents and marketable securities $201.7M at Dec 31, 2024; cash runway extended into H2 2026.
Discontinuing further internal development of vobra duo; seeking partner; Phase 2 TAMARACK rPFS 9.5-10.0 months.
LORIKEET Phase 2 fully enrolled (150 patients); LINNET Phase 2 in ovarian cancer expected mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.